Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis

Conclusions Our data clarify niches within the skin activated in fibrosis and suggest that compounds, such as celastrol, that antagonise the YAP pathway may be potential treatments for SSc skin fibrosis.

http://ard.bmj.com/cgi/content/short/82/9/1191?rss=1

Source: Annals of the Rheumatic Diseases - August 11, 2023 Category: Rheumatology Authors: Chitturi, P., Xu, S., Ahmed Abdi, B., Nguyen, J., Carter, D. E., Sinha, S., Arora, R., Biernaskie, J., Stratton, R. J., Leask, A. Tags: ARD, Connective tissue diseases Source Type: research